Immunovia has today published its report for the third quarter 2021.
| LUND, Sweden, Nov. 11, 2021 /PRNewswire/ -- Immunovia has today published its report for the third quarter 2021. It is available on Immunovia’s website. Patrik Dahlen, CEO: “I am very pleased that we right from the start of the commercialization of our blood test IMMray™ PanCan-d in the USA have received so much positive feedback from the pancreatic cancer community. The largest patient organization with more than 1 million constituents, Pancreatic Cancer Action Network (PanCAN), informed about our test underlining that it is the first-ever blood test specific for pancreatic cancer available to high risk individuals. This strong support is important in achieving the prioritized goal for Immunovia: A successful market penetration in the US market.” Telephone conference Investors, analysts and media are invited to a telephone conference with web presentation today at 16:30 CEST. CEO Patrik Dahlen will present Immunovia and comment on the interim report followed by a Q&A session. The webcasted telephone conference will be held in English. To participate in the telephone conference, please call: Sweden: +46 8 505 583 52 United Kingdom: +44 333 300 92 73 United States: +1 646 722 49 57 Belgium: +32 262 005 47 Denmark: +45 787 232 51 France: +33 170 750 719 Germany: +49 692 222 391 65 Norway: +47 239 636 88 Switzerland: +41 225 805 976 Netherlands: +31 207 219 496 Link to the webcast: https://financialhearings.com/event/14002 Following the telephone conference, a recording will be available on Immunovia’s website (www.immunovia.com). For more information, please contact: This information is information that Immunovia AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 16:00 CET on November 11, 2021. About Immunovia The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden. The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1. In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™ PanCan-d test, the first blood-based test dedicated to the early detection of pancreatic cancer on the market, is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com. Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com. This information was brought to you by Cision http://news.cision.com The following files are available for download:
SOURCE Immunovia AB | ||||
Company Codes: Bloomberg:IMMNOV@SS, ISIN:SE0006091997, RICS:IMMNOV.ST, Stockholm:IMMNOV |
View original content:
